Skip to content
Monday 3 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,870.23
+0.02%
DAX
25,963.45
+1.30%
CAC 40
8,586.38
+0.90%
STOXX 50
6,405.18
+0.74%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 03 November 2009 7:00 pm

GSK and Pfizer launch new firm

By: admindrupal

Add as a preferred source on Google

GlaxoSmithKline and Pfizer yesterday announced the launch of a new HIV company, ViiV Healthcare, dedicated to delivering advances in HIV treatment. Chief executive Dominique Limet yesterday promised a “relentless pursuit” of new treatments. The new company has a mandate to pool the two firms’ existing HIV treatments and drug pipelines. GSK is contributing 90 per cent of £250m start-up costs and will be the major shareholder.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • NULL

Trending Articles

  • Gino D’Acampo restaurants face HMRC winding-up order

  • Goldman Sachs criticises £1.45m paternity payout

  • BP quits North Sea after tax grab

  • Revolut will become $1 trillion company by 2035, says early VC backer

  • Healey announces early Budget

More from City PM

  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Grindr for Equality Commits to Connecting 10M to HIV Prevention by 2028

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Almirall H1 2026 Results

    Business Wire
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook